Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
GLUE surges 44% after sealing a $5.7B licensing deal with NVS to advance molecular glue degraders for immune diseases.
Novartis Catches a ‘Sell.' Goldman Sachs Says the Stock Is Overvalued.
Only 20% of analysts tracked by FactSet rate the stock at Buy.
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver
GLP-1 drugs are taking much oxygen out of the biotechnology trade. However, many investors have been eyeing other areas in the sector, particularly cancer research.
Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range
Novartis on Tuesday said it was buying a U.S. biotech working on a cardiovascular drug, continuing what's been a flurry of acquisitions at a similar price point.
Novartis strikes $1.4bn deal for Tourmaline Bio
Novartis AG (ADR) (NYSE:NVS) has agreed to buy Tourmaline Bio in a $1.4 billion cash deal, strengthening its push into cardiovascular medicine with a late-stage anti-inflammatory drug candidate. Th...
Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal
The deal will boost the Swiss pharmaceutical company's cardiovascular drug pipeline.
Novartis to acquire Tourmaline Bio in deal valuing it at $1.4 billion
Switzerland's Novartis will acquire Tourmaline Bio with an offer price of $48 per share, in a deal valuing the New York-based company at $1.4 billion on a fully diluted basis, it said on Tuesday.
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline's pacibekitug, a long-a...
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular dise...
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising ta...
NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy
Novartis strikes a $200M licensing deal with Arrowhead for ARO-SNCA, aiming to advance treatments for Parkinson???s Disease.
Novartis: Pipeline Progress And Buyback Drive Upside
Novartis delivered strong Q2 results with 24% net income growth and robust sales from key drugs like Kisqali and Pluvicto, supporting our positive outlook. Despite generic competition and tariff co...
Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy
Arrowhead Pharmaceuticals said on Tuesday it will receive up to $2 billion from Novartis for an exclusive worldwide license to its experimental therapy that targets neuromuscular conditions such as...
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
Basel, August 30, 2025 – Novartis today announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio® (inclisiran) compared to placebo, both administered on top of individually ...
Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease
The pharma company said the drug has the potential to become the first and only targeted treatment approved for patients with Sjoegren's disease.
Related Companies